Literature DB >> 10915077

High levels of tumor necrosis factor-alpha and interleukin-1beta in bacterial vaginosis may increase susceptibility to human immunodeficiency virus.

K Sturm-Ramirez1, A Gaye-Diallo, G Eisen, S Mboup, P J Kanki.   

Abstract

Bacterial vaginosis (BV) was identified recently as a cofactor that promotes sexual transmission of human immunodeficiency virus (HIV). This study was done to determine if interleukin (IL)-1beta and tumor necrosis factor (TNF)-alpha could be measured consistently in cervical secretions and if high levels of these cytokines were associated with BV. Secretions were obtained from 209 study subjects; most samples had detectable levels of TNF-alpha (84.2%) and IL-1beta (79.8%). BV was detected in 53 (27.0%) of 196 women. High cytokine levels were significantly associated with BV (adjusted odds ratio [AOR], 4.17; 95% confidence interval [CI], 1.69-10.30), oral contraceptive use (AOR, 2.78; 95% CI, 1.04-7.48), and high leukocyte counts on vaginal smear (AOR, 1.18; 95% CI, 1.03-1.36). Since these cytokines could up-regulate local HIV replication through activation of the long terminal repeat promoter region, the association of BV with high levels of IL-1beta or TNF-alpha may partly explain the mechanism by which this risk factor enhances HIV transmission.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10915077     DOI: 10.1086/315713

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  47 in total

1.  Why common things are common: the tale of non-gonococcal urethritis.

Authors:  M Shahmanesh
Journal:  Sex Transm Infect       Date:  2001-04       Impact factor: 3.519

2.  Effectiveness of vaginal tablets containing lactobacilli versus pH tablets on vaginal health and inflammatory cytokines: a randomized, double-blind study.

Authors:  R Hemalatha; P Mastromarino; B A Ramalaxmi; N V Balakrishna; B Sesikeran
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-07-10       Impact factor: 3.267

Review 3.  Defective virus drives human immunodeficiency virus infection, persistence, and pathogenesis.

Authors:  Diana Finzi; Susan F Plaeger; Carl W Dieffenbach
Journal:  Clin Vaccine Immunol       Date:  2006-07

4.  Cultivation-independent analysis of changes in bacterial vaginosis flora following metronidazole treatment.

Authors:  Michael J Ferris; Johana Norori; Marcela Zozaya-Hinchliffe; David H Martin
Journal:  J Clin Microbiol       Date:  2007-01-03       Impact factor: 5.948

5.  HIV binding, penetration, and primary infection in human cervicovaginal tissue.

Authors:  Diane Maher; Xiaoyun Wu; Timothy Schacker; Julie Horbul; Peter Southern
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-01       Impact factor: 11.205

Review 6.  Microbiome in human immunodeficiency virus infection.

Authors:  January T Salas; Theresa L Chang
Journal:  Clin Lab Med       Date:  2014-09-18       Impact factor: 1.935

Review 7.  Vaginal microbiota and susceptibility to HIV.

Authors:  McKenna C Eastment; R Scott McClelland
Journal:  AIDS       Date:  2018-03-27       Impact factor: 4.177

8.  Human cytomegalovirus and human immunodeficiency virus type-1 co-infection in human cervical tissue.

Authors:  Andrea M Fox-Canale; Thomas J Hope; Jeffrey Martinson; John R Lurain; Alfred W Rademaker; James W Bremer; Alan Landay; Gregory T Spear; Nell S Lurain
Journal:  Virology       Date:  2007-08-22       Impact factor: 3.616

9.  Matrix Metalloproteinases Expressed in Response to Bacterial Vaginosis Disrupt the Endocervical Epithelium, Increasing Transmigration of HIV.

Authors:  Michelle D Cherne; Amy L Cole; Lisa Newberry; Mary Schmidt-Owens; Michael Deichen; Alexander M Cole
Journal:  Infect Immun       Date:  2020-03-23       Impact factor: 3.441

10.  Prevalence and abundance of uncultivated Megasphaera-like bacteria in the human vaginal environment.

Authors:  Marcela Zozaya-Hinchliffe; David H Martin; Michael J Ferris
Journal:  Appl Environ Microbiol       Date:  2008-01-18       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.